TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
G7 Explores AI Access Deal With U.S. Amid Anthropic Restrictions 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
BHP Shares Fall as Jansen Potash Project Costs Surge 
MORRISTOWN, N.J., Dec. 01, 2015 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that Doug Drysdale, Chairman and Chief Executive Officer, and Sanjay Patel, Chief Financial Officer, will present at the Oppenheimer 26th Annual Healthcare Conference as follows:
| Date: | Tuesday, December 8, 2015 | ||||
| Time: | 2:10 p.m. EST | ||||
| Location: | The Westin New York Grand Central, NYC | ||||
The presentation will be webcast and available on the Investors section of the Company’s website at http://www.pernixtx.com/investors/webcasts-presentations/. A replay of the webcast will be available for 30 days after the date of the presentation.
About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and psychiatry, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its Pernix sales force, uses contracted sales organizations to market its non-core, cough and cold products, and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
Investor Relations Sanjay Patel, (800) 793-2145 ext. 1009 Chief Financial Officer [email protected] Lisa Wilson, 212-452-2793 In-Site Communications [email protected] Media Relations Marianne Lambertson, (800) 793-2145 ext. 1012 Vice President, Strategic Development [email protected]
